PMID- 24443791
OWN - NLM
STAT- MEDLINE
DCOM- 20141215
LR  - 20140428
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 80
IP  - 6
DP  - 2014 Jun
TI  - Impact of long-acting octreotide in patients with early-stage MEN1-related 
      duodeno-pancreatic neuroendocrine tumours.
PG  - 850-5
LID - 10.1111/cen.12411 [doi]
AB  - BACKGROUND: Somatostatin analogues (SSA) represent one of the main therapeutic 
      option in patients affected with functioning well-differentiated neuroendocrine 
      tumours (NETs). There are no studies specifically focusing on NETs associated 
      with Multiple Endocrine Neoplasia type 1 (MEN1). AIM: To evaluate the efficacy of 
      the long-acting SSA octreotide in MEN1 patients with early-stage 
      duodeno-pancreatic NETs. PATIENTS AND METHODS: Forty patients with MEN1 were 
      retrospectively evaluated. Twenty patients with evidence of one or more 
      MEN1-related duodeno-pancreatic NETs < 20 mm in size (age range 26-61 years) were 
      treated with octreotide long-acting octreotide (LAR) as first-line therapy. 
      Treatment duration ranged 12-75 months. At the baseline radiological evaluation, 
      multiple duodeno-pancreatic NETs (range 1-8, size 3-18 mm) were detected. 
      RESULTS: An objective tumour response was observed in 10%, stable disease in 80% 
      and progression of disease in 10% of cases. In six patients with abnormally 
      increased CgA, gastrin and/or insulin serum concentrations, a significant 
      clinical and hormonal response occurred in 100% of cases and was stable along the 
      time. CONCLUSIONS: Therapy with SSA is highly safe and effective in patients with 
      early-stage MEN1 duodeno-pancreatic NETs, resulting in long-time suppression of 
      tumour and hormonal activity and 10% objective response. This suggests to early 
      start therapy with SSA in patients with MEN1-related NETs.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Ramundo, V
AU  - Ramundo V
AD  - Department of Clinical Medicine and Surgery, "Federico II" University of Naples, 
      Naples, Italy.
FAU - Del Prete, M
AU  - Del Prete M
FAU - Marotta, V
AU  - Marotta V
FAU - Marciello, F
AU  - Marciello F
FAU - Camera, L
AU  - Camera L
FAU - Napolitano, V
AU  - Napolitano V
FAU - De Luca, L
AU  - De Luca L
FAU - Circelli, L
AU  - Circelli L
FAU - Colantuoni, V
AU  - Colantuoni V
FAU - Di Sarno, A
AU  - Di Sarno A
FAU - Carratu, A C
AU  - Carratu AC
FAU - de Luca di Roseto, C
AU  - de Luca di Roseto C
FAU - Colao, A
AU  - Colao A
FAU - Faggiano, A
AU  - Faggiano A
CN  - Multidisciplinary Group for Neuroendocrine Tumors of Naples
LA  - eng
PT  - Journal Article
DEP - 20140219
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Gastrins)
RN  - 0 (Insulin)
RN  - 51110-01-1 (Somatostatin)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Cell Differentiation
MH  - Disease Progression
MH  - Endocrine System/physiology
MH  - Female
MH  - Gastrins/blood
MH  - Humans
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/complications/*drug therapy
MH  - Neuroendocrine Tumors/complications/*drug therapy
MH  - Octreotide/*therapeutic use
MH  - Retrospective Studies
MH  - Somatostatin/chemistry
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2014/01/22 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/01/22 06:00
PHST- 2013/08/23 00:00 [received]
PHST- 2013/12/22 00:00 [revised]
PHST- 2014/01/13 00:00 [revised]
PHST- 2014/01/13 00:00 [accepted]
PHST- 2014/01/22 06:00 [entrez]
PHST- 2014/01/22 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1111/cen.12411 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2014 Jun;80(6):850-5. doi: 10.1111/cen.12411. Epub 2014 
      Feb 19.